至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Co-opting regulation bypass repair as a gene correction strategy for monogenic diseases

Mol Ther. 2021-04; 
Jingjie Hu, Rebecca A Bourne, Barbara C McGrath, Alice Lin, Zifei Pei, Douglas R Cavener
Products/Services Used Details Operation
PCR Cloning and Subcloning The CopGFP-2cut (Figure S13) for hINS targeting was generated by cloning ITR-U6-BbsI-scaffold-hINSin1(flipped cut site for sg-Reverse)-CopGFP-CDS-SV40pA-3 × 3pCUT-ITR into pUC57-Kan through EcoRV (synthesized by GenScript) Get A Quote

摘要

With the development of CRISPR/Cas9-mediated gene editing technologies, correction of disease-causing mutations has become possible. However, current gene correction strategies preclude mutation repair in post-mitotic cells of human tissues, and a unique repair strategy must be designed and tested for each and every mutation that may occur in a gene. We have developed a novel gene correction strategy, Co-opting Regulation Bypass Repair (CRBR), which can repair a spectrum of mutations in mitotic or post-mitotic cells and tissues. CRBR utilizes the non-homologous end-joining (NHEJ) pathway to insert a coding sequence (CDS) and transcription/translation terminators targeted upstream of any CDS mutation and downstr... More

关键词